Rolley R T, Sterioff S, Parks L C, Williams G M
Transplant Proc. 1977 Mar;9(1):81-3.
A group of 154 patients on chronic dialysis has been evaluated by DNCB reactivity. Viewed as a group, these patients exhibit a highly significant decrease in immunologic responsiveness in comparison to normal individuals. However, 19% of patients had an immunologic response to DNCB and 12% an irritant response. This pretransplant DNCB responsiveness correlated significantly with subsequent allograft rejection in 71 renal allotransplant recipients. For example, at 1 year after transplantation graft survival was strikingly different: DNCB- patients, 78%; DNCB+ patients, 29%; and DNCB-IR patients; 20%. Pretransplant recall-antigen testing results in 32 patients did not correlate significantly with subsequent transplant results. Serial posttransplant delayed cutaneous hypersensitivity responses in patients with a positive response to a skin test antigen in the pretransplant period suggest possible usefulness of this technique for detecting rejection in the posttransplant period. DNCB skin testing should be performed in all transplant candidates to evaluate host responsiveness and should aid in future patient management.
一组154例慢性透析患者接受了二硝基氯苯（DNCB）反应性评估。作为一个整体来看，这些患者与正常个体相比，免疫反应性显著降低。然而，19%的患者对DNCB有免疫反应，12%有刺激反应。这种移植前的DNCB反应性与71例肾同种异体移植受者随后的同种异体移植排斥反应显著相关。例如，移植后1年时移植物存活率有显著差异：DNCB阴性患者为78%；DNCB阳性患者为29%；DNCB刺激反应阳性患者为20%。32例患者移植前回忆抗原检测结果与随后的移植结果无显著相关性。移植前对皮肤试验抗原呈阳性反应的患者移植后系列迟发性皮肤超敏反应提示该技术可能有助于检测移植后排斥反应。所有移植候选者均应进行DNCB皮肤试验，以评估宿主反应性，并有助于未来的患者管理。
